Medicus Pharma findings support women's health pipeline

Medicus Pharma is preparing to present findings from its Phase 1 Teverelix trial, which indicate potential advancements in its women's health pipeline. The data suggests dose-dependent estradiol suppression and a long-acting profile for the drug. These results are scheduled for presentation at AACE 2026, offering promising insights into the therapeutic capabilities of Teverelix for women's health applications.